Alfacell's AC 03-636 increases brain tumor survival rate in animal model

By Lisa Kerner

Erie, Pa., May 10 - Alfacell Corp. said AC 03-636, one of the company's new group of proprietary ribonucleases, significantly prolonged the survival of rats implanted with brain tumors.

The compound has already demonstrated both anti-cancer and anti-viral activity in previous preclinical studies.

In the latest study, AC 03-636 was incorporated into a controlled-release, polyanhydride implant, allowing the drug to be delivered locally at the brain tumor (glioma) site in rats.

When administered intracranially (releasing 70% of the drug over 10 days) on the day of tumor implantation, AC 03-636 significantly prolonged survival of rats, with a median survival of 21 days, compared to the control group median survival of 14 days.

There are approximately 18,000 malignant gliomas diagnosed in the United States each year, according to the American Brain Tumor Association. After diagnosis, patients with malignant gliomas typically live less than 12 months, even with aggressive treatments.

Data from the studies was presented by Joram Slager, Ph.D. of Johns Hopkins University at the American Association of Neurological Surgeons meeting in San Francisco,

Alfacell is a Bloomfield, N.J., biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.